Symbols / PTIX $0.53 -21.83% Protagenic Therapeutics, Inc.
PTIX Chart
About
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.03M |
| Enterprise Value | 2.74M | Income | — | Sales | — |
| Book/sh | -1.24 | Cash/sh | 1.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 1 | IPO | — |
| P/E | — | Forward P/E | -0.91 | PEG | — |
| P/S | — | P/B | -0.43 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | — |
| Current Ratio | — | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -13.13 | EPS next Y | -0.58 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2022-04-07 17:00 | ROA | — |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 1.81M |
| Shs Float | — | Short Float | 3.30% | Short Ratio | 0.56 |
| Short Interest | — | 52W High | 14.28 | 52W Low | 0.25 |
| Beta | — | Avg Volume | 10.85K | Volume | 3.29K |
| Target Price | — | Recom | None | Prev Close | $0.68 |
| Price | $0.53 | Change | -21.83% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.53
Latest analyst target
3. DCF / Fair value
—
Simplified FCF or EPS-based estimate
Ratings
Current target
$0.53
Low
—
High
—
Mean
—
- PTIX SEC Filings - Protagenic Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sun, 05 Apr 2026 11
- Protagenic biotech gains OTCQB listing as depression drug nears Phase 2 - Stock Titan ue, 10 Mar 2026 07
- Protagenic Therapeutics Received Notice of Delisting - TradingView Mon, 05 Jan 2026 08
- Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - livingstondaily.com hu, 27 Nov 2025 08
- PTIX|Protagenic Therapeutics Inc|Price:0.740| - TradingKey hu, 02 Apr 2026 20
- Protagenic Therapeutics Appoints William Nichols as President - The Globe and Mail Wed, 04 Mar 2026 08
- Protagenic settles Phytanix separation, cuts liabilities by $6.3M - Investing.com ue, 17 Mar 2026 07
- Protagenic Therapeutics (PTIX) Streamlines Operations and Focuses on Key Asset - GuruFocus ue, 17 Mar 2026 13
- Protagenic and Phytanix merger prompts a stock surge - BioWorld MedTech Mon, 19 May 2025 07
- If You Invested $1,000 in Protagenic Therapeutics Inc (PTIX) - Stock Titan Mon, 23 Mar 2026 05
- PTIX Faces Market Tremors: Analyzing the Shifts - StocksToTrade hu, 21 Aug 2025 07
- Protagenic Therapeutics Inc (stock code: PTIX) recently disclosed in a filing to the U.S. Securities and Exchange Commission (SEC) that the company officially signed a settlement agreement with former Phytanix shareholders on February 17. - Bitget ue, 24 Feb 2026 08
- Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market - The Globe and Mail ue, 10 Mar 2026 07
- Protagenic slashes $6.3M liabilities to focus on new depression treatment - Stock Titan ue, 17 Mar 2026 07
- Novel Brain Hormone Therapy PT00114 Targets Stress Response: Protagenic's Phase 1 Trial Advances - Stock Titan hu, 21 Aug 2025 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
5.70
+25.93%
|
4.53
+27.24%
|
3.56
-14.07%
|
4.14
|
| Research And Development |
|
3.94
+18.75%
|
3.32
+108.90%
|
1.59
+39.80%
|
1.14
|
| Selling General And Administration |
|
1.76
+45.69%
|
1.21
-38.68%
|
1.97
-34.46%
|
3.00
|
| General And Administrative Expense |
|
1.76
+45.69%
|
1.21
-38.68%
|
1.97
-34.46%
|
3.00
|
| Other Gand A |
|
1.76
+45.69%
|
1.21
-38.68%
|
1.97
-34.46%
|
3.00
|
| Total Expenses |
|
5.70
+25.93%
|
4.53
+27.24%
|
3.56
-14.07%
|
4.14
|
| Operating Income |
|
-5.70
-25.93%
|
-4.53
-27.24%
|
-3.56
+14.07%
|
-4.14
|
| Total Operating Income As Reported |
|
-5.70
-25.93%
|
-4.53
-27.24%
|
-3.56
+14.07%
|
-4.14
|
| EBITDA |
|
-5.48
-12.55%
|
-4.86
-42.32%
|
-3.42
+15.10%
|
-4.03
|
| Normalized EBITDA |
|
-5.53
-30.52%
|
-4.23
-25.57%
|
-3.37
+17.90%
|
-4.11
|
| Reconciled Depreciation |
|
0.05
+78.21%
|
0.03
+93960.00%
|
0.00
|
0.00
|
| EBIT |
|
-5.53
-12.93%
|
-4.89
-43.15%
|
-3.42
+15.10%
|
-4.03
|
| Total Unusual Items |
|
0.05
+108.21%
|
-0.63
-1268.74%
|
-0.05
-156.72%
|
0.08
|
| Total Unusual Items Excluding Goodwill |
|
0.05
+108.21%
|
-0.63
-1268.74%
|
-0.05
-156.72%
|
0.08
|
| Net Income |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Pretax Income |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Net Non Operating Interest Income Expense |
|
0.04
-72.28%
|
0.16
+224.40%
|
0.05
+110.42%
|
-0.46
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.11
-21.66%
|
0.14
-72.34%
|
0.50
|
| Net Interest Income |
|
0.04
-72.28%
|
0.16
+224.40%
|
0.05
+110.42%
|
-0.46
|
| Interest Expense |
|
0.00
-100.00%
|
0.11
-21.66%
|
0.14
-72.34%
|
0.50
|
| Interest Income Non Operating |
|
0.04
-83.57%
|
0.26
+42.35%
|
0.19
+459.49%
|
0.03
|
| Interest Income |
|
0.04
-83.57%
|
0.26
+42.35%
|
0.19
+459.49%
|
0.03
|
| Other Income Expense |
|
0.13
+120.96%
|
-0.63
-1268.74%
|
-0.05
-156.72%
|
0.08
|
| Other Non Operating Income Expenses |
|
0.08
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.05
+108.21%
|
-0.63
-1268.74%
|
-0.05
-156.72%
|
0.08
|
| Tax Provision |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Net Income From Continuing Operation Net Minority Interest |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Net Income From Continuing And Discontinued Operation |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Net Income Continuous Operations |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Normalized Income |
|
-5.58
-27.62%
|
-4.37
-24.53%
|
-3.51
+23.78%
|
-4.60
|
| Net Income Common Stockholders |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Diluted EPS |
|
-15.82
+1.74%
|
-16.10
-40.24%
|
-11.48
+33.87%
|
-17.36
|
| Basic EPS |
|
-15.82
+1.74%
|
-16.10
-40.24%
|
-11.48
+33.87%
|
-17.36
|
| Basic Average Shares |
|
0.35
+12.78%
|
0.31
+0.62%
|
0.31
+17.17%
|
0.26
|
| Diluted Average Shares |
|
0.35
+12.78%
|
0.31
+0.62%
|
0.31
+17.17%
|
0.26
|
| Diluted NI Availto Com Stockholders |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
1.96
-54.76%
|
4.32
-46.21%
|
8.04
-27.33%
|
11.06
|
| Current Assets |
|
1.88
-55.17%
|
4.20
-47.73%
|
8.04
-27.34%
|
11.06
|
| Cash Cash Equivalents And Short Term Investments |
|
1.84
-54.67%
|
4.06
-49.16%
|
7.98
-23.07%
|
10.37
|
| Cash And Cash Equivalents |
|
1.84
+42.75%
|
1.29
+498.49%
|
0.22
-60.24%
|
0.54
|
| Cash Financial |
|
1.84
+42.75%
|
1.29
+498.49%
|
0.22
-60.24%
|
0.54
|
| Other Short Term Investments |
|
0.00
-100.00%
|
2.77
-64.34%
|
7.76
-21.02%
|
9.83
|
| Prepaid Assets |
|
0.04
-69.17%
|
0.14
+152.95%
|
0.06
-91.73%
|
0.69
|
| Total Non Current Assets |
|
0.07
-40.77%
|
0.12
+6848.28%
|
0.00
|
0.00
|
| Net PPE |
|
0.07
-40.77%
|
0.12
+6848.28%
|
0.00
|
0.00
|
| Total Liabilities Net Minority Interest |
|
0.94
+43.88%
|
0.66
-41.49%
|
1.12
+0.17%
|
1.12
|
| Current Liabilities |
|
0.94
+43.88%
|
0.66
-41.49%
|
1.12
+40.06%
|
0.80
|
| Payables And Accrued Expenses |
|
0.94
+43.88%
|
0.66
-15.52%
|
0.78
-2.99%
|
0.80
|
| Payables |
|
0.10
-9.53%
|
0.11
-26.81%
|
0.16
-44.26%
|
0.28
|
| Accounts Payable |
|
0.10
-9.53%
|
0.11
-26.81%
|
0.16
-44.26%
|
0.28
|
| Current Accrued Expenses |
|
0.84
+55.10%
|
0.54
-12.69%
|
0.62
+19.13%
|
0.52
|
| Current Debt And Capital Lease Obligation |
|
—
|
—
|
0.34
|
—
|
| Current Debt |
|
—
|
—
|
0.34
|
—
|
| Other Current Borrowings |
|
—
|
—
|
0.34
|
—
|
| Other Current Liabilities |
|
—
|
—
|
—
|
0.00
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
-100.00%
|
0.32
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.32
|
| Long Term Debt |
|
—
|
—
|
—
|
0.32
|
| Stockholders Equity |
|
1.01
-72.38%
|
3.67
-46.97%
|
6.92
-30.42%
|
9.94
|
| Common Stock Equity |
|
1.01
-72.38%
|
3.67
-46.97%
|
6.92
-30.42%
|
9.94
|
| Capital Stock |
|
0.00
+63.29%
|
0.00
+2.30%
|
0.00
+0.46%
|
0.00
|
| Common Stock |
|
0.00
+63.29%
|
0.00
+2.30%
|
0.00
+0.46%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
0.52
+63.27%
|
0.32
+2.63%
|
0.31
+0.44%
|
0.31
|
| Ordinary Shares Number |
|
0.52
+63.27%
|
0.32
+2.63%
|
0.31
+0.44%
|
0.31
|
| Additional Paid In Capital |
|
37.45
+8.35%
|
34.56
+3.56%
|
33.37
+2.96%
|
32.41
|
| Retained Earnings |
|
-36.30
-17.95%
|
-30.78
-19.40%
|
-25.78
-16.00%
|
-22.22
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.13
-14.36%
|
-0.11
+83.23%
|
-0.68
-172.56%
|
-0.25
|
| Other Equity Adjustments |
|
-0.13
-14.36%
|
-0.11
+83.23%
|
-0.68
-172.56%
|
-0.25
|
| Total Equity Gross Minority Interest |
|
1.01
-72.38%
|
3.67
-46.97%
|
6.92
-30.42%
|
9.94
|
| Total Capitalization |
|
1.01
-72.38%
|
3.67
-46.97%
|
6.92
-32.58%
|
10.26
|
| Working Capital |
|
0.94
-73.48%
|
3.54
-48.74%
|
6.92
-32.60%
|
10.26
|
| Invested Capital |
|
1.01
-72.38%
|
3.67
-49.49%
|
7.26
-29.23%
|
10.26
|
| Total Debt |
|
—
|
—
|
0.34
+8.10%
|
0.32
|
| Net Debt |
|
—
|
—
|
0.13
|
—
|
| Net Tangible Assets |
|
1.01
-72.38%
|
3.67
-46.97%
|
6.92
-30.42%
|
9.94
|
| Tangible Book Value |
|
1.01
-72.38%
|
3.67
-46.97%
|
6.92
-30.42%
|
9.94
|
| Line Item | Trend | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-4.22
-13.84%
|
-3.70
-85.76%
|
-1.99
+28.76%
|
-2.80
|
| Cash Flow From Continuing Operating Activities |
|
-4.22
-13.84%
|
-3.70
-85.76%
|
-1.99
+28.76%
|
-2.80
|
| Net Income From Continuing Operations |
|
-5.53
-10.50%
|
-5.00
-40.64%
|
-3.56
+21.39%
|
-4.52
|
| Depreciation Amortization Depletion |
|
0.05
+78.21%
|
0.03
+93960.00%
|
0.00
|
0.00
|
| Depreciation |
|
0.05
+78.21%
|
0.03
+93960.00%
|
0.00
|
0.00
|
| Depreciation And Amortization |
|
0.05
+78.21%
|
0.03
+93960.00%
|
0.00
|
0.00
|
| Other Non Cash Items |
|
-0.08
-193.75%
|
0.09
-22.59%
|
0.11
-74.06%
|
0.43
|
| Stock Based Compensation |
|
0.92
+38.44%
|
0.67
-22.88%
|
0.86
-43.07%
|
1.52
|
| Operating Gains Losses |
|
-0.05
-108.21%
|
0.63
+1268.74%
|
0.05
+156.72%
|
-0.08
|
| Gain Loss On Investment Securities |
|
-0.05
-108.21%
|
0.63
+1268.74%
|
0.05
+156.72%
|
-0.08
|
| Change In Working Capital |
|
0.47
+508.65%
|
-0.11
-121.18%
|
0.54
+484.74%
|
-0.14
|
| Change In Prepaid Assets |
|
0.10
+214.40%
|
-0.09
-113.79%
|
0.63
+231.47%
|
-0.48
|
| Change In Payables And Accrued Expense |
|
0.37
+1446.40%
|
-0.03
+70.17%
|
-0.09
-126.93%
|
0.34
|
| Investing Cash Flow |
|
2.80
-41.31%
|
4.78
+199.03%
|
1.60
+116.12%
|
-9.91
|
| Cash Flow From Continuing Investing Activities |
|
2.80
-41.31%
|
4.78
+199.03%
|
1.60
+116.12%
|
-9.91
|
| Net PPE Purchase And Sale |
|
0.00
+100.00%
|
-0.15
-8197.78%
|
-0.00
|
0.00
|
| Purchase Of PPE |
|
0.00
+100.00%
|
-0.15
-8197.78%
|
-0.00
|
0.00
|
| Capital Expenditure |
|
—
|
-0.15
-8197.78%
|
-0.00
|
—
|
| Net Investment Purchase And Sale |
|
2.80
-43.09%
|
4.93
+208.06%
|
1.60
+116.13%
|
-9.91
|
| Purchase Of Investment |
|
-0.30
+89.25%
|
-2.76
-8001.08%
|
-0.03
+99.67%
|
-10.40
|
| Sale Of Investment |
|
3.10
-59.69%
|
7.69
+370.91%
|
1.63
+236.03%
|
0.49
|
| Financing Cash Flow |
|
1.96
|
0.00
|
0.00
-100.00%
|
12.58
|
| Cash Flow From Continuing Financing Activities |
|
1.96
|
0.00
|
0.00
-100.00%
|
12.58
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
|
0.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
|
0.00
|
| Long Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Net Long Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.10
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.10
|
| Net Common Stock Issuance |
|
1.96
|
0.00
|
0.00
-100.00%
|
11.71
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
-100.00%
|
0.87
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
11.71
|
| Changes In Cash |
|
0.55
-48.69%
|
1.07
+370.06%
|
-0.40
-203.97%
|
-0.13
|
| Effect Of Exchange Rate Changes |
|
0.00
-33.17%
|
0.00
-98.59%
|
0.07
+11129.48%
|
0.00
|
| Beginning Cash Position |
|
1.29
+498.49%
|
0.22
-60.24%
|
0.54
-19.36%
|
0.67
|
| End Cash Position |
|
1.84
+42.75%
|
1.29
+498.49%
|
0.22
-60.24%
|
0.54
|
| Free Cash Flow |
|
-4.22
-9.42%
|
-3.85
-93.10%
|
-2.00
+28.69%
|
-2.80
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Income Tax Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
1.96
|
0.00
|
0.00
-100.00%
|
11.71
|
| Issuance Of Capital Stock |
|
1.96
|
0.00
|
0.00
-100.00%
|
11.71
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-03-09 View
- 8-K2026-03-03 View
- 8-K2026-02-24 View
- 8-K2026-01-05 View
- 10-Q2025-11-26 View
- 8-K2025-11-26 View
- 8-K2025-11-05 View
- 8-K2025-10-31 View
- 8-K2025-08-22 View
- 8-K2025-08-13 View
- 8-K2025-07-30 View
- 8-K2025-07-24 View
- 8-K2025-06-27 View
- 8-K2025-05-21 View
- 8-K2025-05-20 View
- 8-K2025-05-19 View
- 10-Q2025-05-13 View
- 8-K2025-05-05 View
- 8-K2025-04-29 View
- 8-K2025-04-18 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|